Table 1. atient characteristics and clinicopathological variables, and their prognostic value for the biochemical and clinical failure in 535 prostate cancer patients (univariate analyses; log rank test).

Characteristic	Patients (n)	Patients (%)	BF (200 events)		CF (56 events)
			5-year EFS (%)	p	10-year EFS (%)	p
Age				0.237		0.038
≤ 65 years	357	67	77		94
>65 years	178	33	70		91
pT-stage				<0.001		<0.001
pT2	374	70	83		97
pT3a	114	21	61		87
pT3b	47	9	43		74
Preop PSA				<0.001		0.029
PSA < 10	308	57	81		95
PSA > 10	221	42	68		89
Missing	6	1	—		—
Gleason				<0.001		<0.001
3 + 3	183	34	83		98
3 + 4	219	41	77		94
4 + 3	81	15	70		90
4 + 4	17	4	58		86
≥9	35	6	37		65
Tumor Size				<0.001		0.002
0–20 mm	250	47	83		96
>20 mm	285	53	68		90
PNI				<0.001		<0.001
No	401	75	80		96
Yes	134	25	60		83
PSM				0.049		0.198
No	249	47	81		96
Yes	286	53	69		90
Non-apical PSM				<0.001		<0.001
No	381	71	82		96
Yes	154	29	57		85
Apical PSM				0.063		0.427
No	325	61	74		92
Yes	210	39	77		93
LVI				<0.001		<0.001
No	492	92	77		95
Yes	43	8	47		69
Surgical proc				0.466		0.308
Retropubic	435	81	77		92
Perineal	100	19	68		95
Tumor cell miR-210				0.85		0.09
High expression	162	30	73		91
Low expression	183	34	73		94
Missing	190	36
Fibroblast miR-210				0.23		0.001
High expression	310	58	74		90
Low expression	187	35	79		97
Missing	38	7

Abbreviations: BF = biochemical failure; CF = Clinical failure; EFS = event free survival in months; LVI = lymphovascular infiltration, PCD = prostate cancer death; NR= not reached; P = P value for log rank statistic for difference in event free survival; PC = Prostate cancer; PNI = Perineural infiltration; Post op RT = postoperative radiotherapy; Preop = preoperative; PSA=Prostate specific antigen; PSM = Positive surgical margin; Surgical proc = surgical procedure;